Subscribe to the newsletterForward | Contact |   July 2015
04/09/2015 - Apply to BlueSky Meeting!

The 4th edition of BlueSky Meeting will take place on October 7th 2015 in Lyon during the Partnering Days of Lyonbiopole. This event, which objective is to enhance the partnerships between public and private healthcare players in Rhône-Alpes, will allow you to present your technological offer of project idea open to partnership. The call is also opened to academic and industrial members of the BioWin cluster, based in Wallonia. If you want to take part to this unique event in the region, you can apply until September, 4th 2015.
Call for applications and registration form.
Contact : Hugo Veysseyre, Clinical Innovation Project Manager -  

Learn more

10/07/2015 - The 9th edition of the Partnering Days

The 9th edition of the Partnering Days will take place on October, 7th 2015 at l'Hôtel de Région (Lyon-Confluence). The target of the event, organised by Lyonbiopole, is to create R&D partnerships in the health sector between public and private actors in Rhône-Alpes.
Contact : Claudia Chagneau, R&D Project Manager - 

Learn more

10/07/2015 - Lyonbiopole is celebrating its 10th anniversary

Join us on October, 7th at 4.30 p.m at l'Hôtel de Région (Lyon - Confluence). The cluster's team and its administrators will be pleased to welcome you to share a friendly and festive time. Save-the-date... Invitations and program will soon be sent!  
Contact : Stéphanie Pelege, Communication Manager

Learn more

Pragma Therapeutics

Pragma Therapeutics is a biopharmaceutical company working in the field of neuroscience and member of Lyonbiopole. Pragma Therapeutics focuses its activities on the discovery and development of small molecule therapeutics acting at a brain-specific protein localized in discrete regions involved in the regulation of stress. The company has recently established a collaboration with Pulsalys, a start-up incubator based in Lyon. A FrenchTech grant co- financed by BPIFrance and INPI, has also just been attributed to Pragma to monetize patenting and accurate market analysis.

Learn more

09/16/2015 - Symposium on innovative expression systems

Accinov and BIOASTER organize a one-day symposium on breakthrough innovation in expression systems and alternative expression platforms. You will discover the foremost technology ranging from prokaryotic systems to complex plants and protozoa. Speakers will come from all across Europe to contribute to this unique event! Innovation in the field of genetic engineering will also be discussed. Learn more about the program. To register,please fill the e-Registration form.
Contact : Sylvain Peyrache, Accinov -
Régis Sodoyer -  
Emilie Bernard -

Learn more

09/23-24/2015 - Seminar on proteins and peptides stability

The association Adebiotech organizes a seminar on proteins and peptides stability and formulation. The seminar will be held in Romainville, on September, 24th and 25th. Accinov supports the preparation of the agenda of the seminar where challenges and opportunities of proteins and peptides formulation will be addressed. Attend the seminar and discover how to anticipate risks of instability, the foremost analytical methods available; how to model these phenomena and what are the latest formulation technologies to develop new biologics.
Contact : Sylvain Peyrache, Accinov

Learn more

09/29/2015 - 3rd edition of Health TechDays

The event will be held in the World Trade Center of Grenoble on September 29, 2015. Organized by I-Care, in partnership with Lyonbiopole and MEDIC@LPS. The day is particularly dedicated to sector companies (solution developers and their subcontractors), to healthcare professionals and to researchers. The day is organised around: plenary sessions, B2B meetings and the opportunity to move accross the showroom.
Contact : Nicolas Groux, Medical Technologies Project Manager  - 

Learn more

12/04/2015 - Save the date : 7th edition of Private Inv€stments Day

This event organized by Lyonbiopole, will be held on Friday, December 4, 2015, at Sanofi Pasteur headquarters. The objective is to facilitate and develop contacts among SMEs and private investors. The full program is still at the editing stage. It will be submitted shortly.
Contact : Simon Gudin, SMEs Development Project Manager - 

Learn more

Symposium Accinov/BIOASTER
September 16th, 2015 - Lyon, France 
Summer School Asset 
From September 21st to 24th, 2015 - Roma, Italy 
Adebiotech seminar on proteins and peptides stability
From September 23th to 24th, 2015 - Romainville, France
Health TechDays
September 29th, 2015 - Grenoble, France 
Innovation Days
October 5th to 6th, 2015 - Paris, France
Partnering Days
October 7th, 2015 - Lyon, France
October 13th to 16th - Tokyo, Japan
BIO-Europe 2015
November 2nd to 4th, 2015 - Munich, Germany
BioFIT Fostering Innovation & Transfer
From December, 1st to 2nd, 2015 - Strasbourg, France
Private Inv€stments Day
December 4th,  2015 - Lyon, France
European Nanomedecine Meeting
December 7th to 9th, 2015 - Grenoble, France
03/2015 - H2020 Instrument PME

H2020 program includes the SME instrument. It targets the highly innovative SMEs with a strong ambition to develop, grow and internationalize;  focusing on the delivery of new products, services or processes on the market. For SMEs in the health sector, the SME instrument is focused on the PHC-12 Clinical research for the validation of biomarkers and diagnostic medical devices line. The project can be presented by a single SME, and different phases depending on the maturity of the project. Next submission deadline: Phase 1 & 2 projects = 09/17/2015 and 11/25/2015 . Lyonbiopole supports you to build up European projects.
Contact : Emilie Romeo, European Project Manager 

Learn more

01/2015 - Fast Track to Innovation

The European Commission launches a new initiative Fast Track to Innovation (FTI) under H2020. It aims to give to innovative companies a final push before the access to market. The projects must focus on industrial development. Consortia should bring 3-5 organizations (mostly companies). All fields of technology are concerned. Several submission dates are planned in 2015 (09/01/2015 and 12/1/2015). 
Contact : Emilie Romeo, European Project Manager -

Learn more

03/2015 - Eurostars call for projects

Eurostars call for projects is open. This funding programme is fully dedicated to innovative SMEs aiming to launch R&D projects closed to the market, that are collaborative and European (at least 2 partners from EU). The funding rate for projects goes from 30 to 40% (subsidy managed by BPI France). The submission deadline is fixed on 09/17/2015. Lyonbiopole supports you to build up European projects.
Contact : Emilie Romeo, European Project Manager  -

Learn more

07/2015 - 09/2015 : Looking for opportunities in Autoimmune Diseases with Asahi KASEI (Japon)

With the aging of the Japanese population, we face an ever-increasing incidence of metabolic bone diseases and rheumatoid arthritis. Asahi Kasei Pharma has strived to improve the standards of care for these diseases. In this context, the company launched a collaborative call for project. A research background will be awarded to the company choosen, over a maximum period of 3 years.
Contact : Simon Gudin, SMEs Development Project 

Learn more

06/15-18/2015 - BIO 2015, a good year for Rhône-Alpes delegation

On the occasion of BIO International Convention, Philadelphia June 15 to 18, 20 Rhône-Alpes’ SMEs were present on Lyonbiopole’s booth on the French Pavilion. This delegation, which was the largest on the pavilion, shows the importance of the Rhône-Alpes health industry worldwide. 4 Lyonbiopole’s members had the opportunity to continue their exploration of the US market through their participation in BIO+, a mission organised by the French American Chamber of Commerce and Lyonbiopole. During this mission, the participants met UPenn, the Wistar Institute and Princeton University for future partnerships.
Contact : Simon Gudin, SMEs Development Project Manager -

07/28/2015 - Success for the TYROMAB project

After its accreditation by Lyonbiopole and Alsace BioValley, worldwide competitiveness clusters, the TYROMAB project has just been selected by the 20th Call for Projects of the Single Inter-Ministry Fund (FUI). This project aims to develop both the French biomanufacturing industry and reduce the burden of cancer through the development of a therapeutic antibody against metastatic bladder cancer and leiomyosarcoma. To meet these major challenges, TYROMAB brings together two industrial players : ElsaLys Biotech and Aguettant group and an academic actor recognized worldwide for its scientific and clinical expertise in the field of Oncology, the Centre Léon Bérard. This project will benefit from public funding from the French State, local authorities among which the Rhône-Alpes Region, Alsace Region, Strasbourg Eurométropole and FEDER European funds.

07/25/2015 - Cartimage, laureate of "i-LAB"

Cartimage is a laureate of the French Ministry of Research's 17th annual startup competition, "i-LAB", in the "creation-development" category. Along with the recognition of Cartimage's technology and business model, this award comes with substantial financial support from the French public investment bank Bpifrance.

Learn more

07/2015 - Erytech Pharma July actuality

ERYTECH Pharman annonced the 20th, positive safety review for ERY-ASP in its phase 2 study in pancreatic cancer. This study conducted in France, has about 90 patients. The primary endpoint is progression-free survival at 4 months. In july, the 16th, Erytech appoints Dr. Iman El-Hariry as chief medical officier. This oncologist has more than 15 years of global product development experience in the global biopharmaceutical industry, including as VP Clinical Research with Syntha Pharmaceuticals (Boston), Global Head Oncology at Astellas APGD (Chicago) and Group Director Clinical Oncology at GSK (London).

07/2015 - ImmunID July actuality

On July 22, ImmunID announced obtaining key patents in the United States, Europe, Canada and Japan covering the underlying technology of the ImmunTraCkeR® and ImmunIG® assays, which are evaluating a patient’s own immune system, both T-Cell repertoire and B-Cell repertoire. The company announced on July 7, the publication of a short report in the Journal for ImmunoTherapy of Cancer (JITC) showing that the analysis of peripheral T cell receptor diversity using the company’s ImmunTraCkeR® assay is associated with clinical outcomes following Ipilimumab treatment in metastatic melanoma. Finally, earlier this month, the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to ImmunID’s laboratory based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs

07/02/2015 - Elsalys Biotech acquires a first-in-class antibody with a dual biological mechanism of action

Elsalys Biotech announced the acquisition of the development and marketing rights of the anti-CD160 antibody from the company MABLIFE. The result of this study, which should lead to the selection of a first drug candidate, is expected in the first half of 2016.

Learn more

© Lyonbiopole 2021  |  CREDITS  |  LEGAL NOTICE  |